Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous worldwide licensing agreement. The deal sees Ichnos licensing its prized OX40 antagonist monoclonal antibody portfolio to Astria Therapeutics, a biopharmaceutical powerhouse dedicated to developing cutting-edge therapies for rare allergic and […]